Infection in asymptomatic carriers of SARS-CoV-2 can interfere with the achievement of robust immunity on a population scale

J Gen Virol. 2021 Nov;102(11):001684. doi: 10.1099/jgv.0.001684.

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread worldwide as a severe pandemic, and a significant portion of the infected population may remain asymptomatic. Given this, five surveys were carried out between May and September 2020 with a total of 3585 volunteers in the municipality of Foz do Iguaçu, State of Paraná, a triple border region between Brazil/Argentina/Paraguay. Five months after the first infection, volunteers were re-analysed for the production of IgG anti-Spike and anti-RBD-Spike, in addition to analyses of cellular immunity. Seroconversion rates ranged from 4.4 % to a peak of 37.21 % followed by a reduction in seroconversion to 21.1 % in September, indicating that 25 % of the population lost their circulating anti-SARS-CoV-2 antibodies 3 months after infection. Analyses after 5 months of infection showed that only 17.2 % of people still had anti-RBD-Spike antibodies, however, most volunteers had some degree of cellular immune response. The strategy of letting people become naturally infected with SARS-CoV-2 to achieve herd immunity is flawed, and the first contact with the virus may not generate enough immunogenic stimulus to prevent a possible second infection.

Keywords: SARS-CoV-2; cell immunity; herd immunity; humoral immunity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Viral / immunology
  • Argentina / epidemiology
  • Brazil / epidemiology
  • COVID-19 / epidemiology
  • COVID-19 / immunology*
  • COVID-19 / virology
  • Carrier State / epidemiology
  • Carrier State / immunology*
  • Carrier State / virology
  • Humans
  • Immunity, Cellular
  • Immunity, Herd*
  • SARS-CoV-2 / genetics
  • SARS-CoV-2 / immunology*
  • SARS-CoV-2 / physiology
  • Spike Glycoprotein, Coronavirus / immunology

Substances

  • Antibodies, Viral
  • Spike Glycoprotein, Coronavirus